Legally Poisoned

Carl Cranor
Department of Philosophy
University of California
Riverside, CA
Molecules can also pose risks or cause harms, but diagnosing their adverse effects is much more subtle and difficult than for the grosser forms of violence.

Diethylstilbestrol
In utero exposure caused cervical cancer at age 20, breast cancer later.

How can we utilize the law and science to reduce the risks to children from toxic molecules?
Highlights of Some Recent Science

- U.S. citizens are contaminated by up to 212 manmade substances; there will be more (CDC, 2009).

- Women’s contamination is shared with developing children *in utero* -- the placenta is no significant barrier.

- Children have been born with up to 232 industrial chemicals in their bodies.
Women’s Chemical Burden is Shared with Developing Fetuses and Newborns

- 1965: The womb was seen as a time capsule, relatively impermeable to circulating drugs or toxicants. (Needleman & Bellinger, 1994)

- Contradicted by the social catastrophes of methylmercury (1960s), thalidomide (1960s), and DES (1971).

- Now much more evidence.
Women’s Chemical Burden is Shared with Developing Fetuses and Newborns

- There is “no placental barrier per se: the vast majority of chemicals given the pregnant animal (or woman) reach the fetus in significant concentrations soon after administration.” (Schardein, 2002)

- Plastic nanoparticles can move from mom to baby through placenta. 29 March 2010 “Research shows for the first time that plastic nanoparticles can cross the human placenta, possibly exposing the developing fetus to the tiny materials that are increasingly used in medicines, vaccines and personal care products.” (EHN.org)
Development is a genetic program

Mother is the fetal incubator

Development is an open system (developmental plasticity, ECO-DEVO)

Mother is the fetal environment

- light
- food
- hormones
- toxicants

Courtesy: Ana Soto
Developing Children Have Greater Exposures

- They are exposed to larger doses of toxicants relative to the body weight than the mother, via cord blood and breast milk. (Faroe’s Statement, 2007)

  - Lipophilic substances will be concentrated in cord blood and breast milk (PCBs up to 100 times greater). (Heinzow, et. al., 2007)

  - Mercury concentrations can be at least 5 times higher in fetal brain than in mother’s blood.

  - E.g., lead is mobilized as part of the “calcium stream” in pregnant women. (Bellinger & Needleman, 1994)
Developing Children Have Greater Exposures

They have

- Higher metabolism, breathing, absorption rates. (Miller, et. al.)
- Higher fluid and food intake rates per body weight. (Miller, et. al.)

They play close to ground/floor, “mouth” everything.
Developing Children

- Have greater exposures.
- Are more susceptible.
- Have lesser defenses (less developed immune system, underdeveloped blood brain barrier, underdeveloped detoxifying enzymes).
Genetic Variation Can Add to The Vulnerability

- Some developing children are more susceptible to polycyclic aromatic hydrocarbons (byproducts of combustion, e.g., tobacco smoke, urban smoke). (Perrara, et. al.)

- Some are more susceptible to organophosphate pesticides. (Eskenazi, et. al., 2008)
Generalized Additive Affects Can Increase Vulnerability

- Substances can affect different “upstream” pathways producing jointly additive effects, but not affecting the same cellular receptors:
  - Dioxin-like PCBs affect one pathway, reducing thyroid concentrations in pregnant women, creating neurological hazards to fetuses.
  - Non-dioxin-like PCBs affect another pathway with the same results. (Woodruff, et. al., EHP, 2008)
  - Brominated fire retardants (PBDEs) likely have similar effects because of similarity to non-dioxin-like PCBs.
Some Conclusions

- Molecular or nano contamination are not the problem; that is inevitable, unavoidable.
- Contamination by toxicants is the problem.
- We must determine the toxicity of molecules and nano particles before the public and workforce are exposed; otherwise citizens become experimental subjects.
- The law permits toxic contamination; it can prevent it.
## General recommendations summary

<table>
<thead>
<tr>
<th>Hazard ID and exposure potential</th>
<th>1. Develop a description of nanomaterials</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2. Define unique properties and collect this information to be reported</td>
</tr>
<tr>
<td></td>
<td>3. Group nanomaterials by characteristic (i.e. size, surface charge, specific application)</td>
</tr>
<tr>
<td>Identifying sources of nanomaterials</td>
<td>4. Gather information about types of NPs and uses</td>
</tr>
<tr>
<td></td>
<td>5. Require reporting of manufacturing quantities and products, including an inventory clearinghouse of information</td>
</tr>
<tr>
<td>Addressing Exposure</td>
<td>6. Collect information on fate &amp; transport</td>
</tr>
<tr>
<td></td>
<td>7. Decisions should be made with use, exposure and benefit in mind</td>
</tr>
<tr>
<td></td>
<td>8. Require testing for exposure &amp; release potential of NPs</td>
</tr>
<tr>
<td>Too postmarket</td>
<td>9. Increase efforts to protect and educate workers, manufacturers, researchers and downstream users of nanomaterials:</td>
</tr>
<tr>
<td>Health Effects</td>
<td>10. Use existing hazard traits, toxicological endpoints and health effects to estimate risk</td>
</tr>
<tr>
<td></td>
<td>11. Review current regulatory structure to see if nanomaterials can be incorporated</td>
</tr>
<tr>
<td></td>
<td>12. Targeted research on fate, transport and health effects</td>
</tr>
<tr>
<td>Product testing</td>
<td>13. Increase communication with governments, manufacturers and researchers</td>
</tr>
<tr>
<td>Engaging and informing the public</td>
<td>14. Require toxicology testing for consumer products (preferably pre-market)</td>
</tr>
<tr>
<td></td>
<td>15. Implement a labeling system</td>
</tr>
<tr>
<td></td>
<td>16. Include the public in decision processes</td>
</tr>
</tbody>
</table>
Thank you